Share
Regenerative medicine, federal investment, information sharing, and challenges in an evolving field: report to congressional requesters. (in English)
U. S. Government Accountability Office
(Author)
·
Createspace Independent Publishing Platform
· Paperback
Regenerative medicine, federal investment, information sharing, and challenges in an evolving field: report to congressional requesters. (in English) - Office, U. S. Government Accountability
$ 11.99
$ 14.99
You save: $ 3.00
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My WishlistsIt will be shipped from our warehouse between
Wednesday, July 17 and
Thursday, July 18.
You will receive it anywhere in United States between 1 and 3 business days after shipment.
Synopsis "Regenerative medicine, federal investment, information sharing, and challenges in an evolving field: report to congressional requesters. (in English)"
" Regenerative medicine is an interdisciplinary field with a focus on conducting research and developing treatments for a vast assortment of previously untreatable diseases and conditions through self-healing-a process by which the body uses its own systems to recreate cells and rebuild tissues and organs. GAO was asked to review the federal involvement in this field. This report describes (1) which federal agencies conducted or funded regenerative medicine research in recent years and how these agencies invested their resources; (2) the activities these federal agencies undertake to share information across agencies; and (3) the challenges to advancing the field of regenerative medicine identified by federal agencies and other stakeholders and the steps taken, if any, to address them. GAO analyzed funding data from seven federal agencies active in regenerative medicine research in fiscal years 2012 through 2014, the 3 most recent years for which full funding data were available; reviewed agency documents, including reports and strategic plans, and an interagency working group's meeting agendas and minutes. GAO also interviewed officials from the seven agencies, as well as nonfederal stakeholders, representing academic and state-funded research institutions, patient advocacy groups"